$BHST News

BioHarvest takes second plant-cell asset to commercial readiness

BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity

BioHarvest Sciences' Proprietary Olive Cell Composition Attains Commercial Readiness, Now Available For Licensing And Commercialization

Tate & Lyle (LSE:TATE) Reaches Next Generation Sweetener Milestone

BioHarvest says its platform can produce target sweetener in Tate & Lyle program

Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme

BioHarvest Sciences launches buyback of up to 5% of shares

BioHarvest Sciences Announces Share Repurchase Program

BioHarvest Sciences Board Authorizes Normal Course Issuer Bid To Repurchase Up To 5% Of Outstanding Common Shares

BioHarvest Sciences launches single-dose VINIA Daily Chews

BioHarvest Advances Botanical Synthesis Leadership as VINIA Daily Chews Unlock More Value from Its First Consumer Product

BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

BioHarvest Sciences plans Tel Aviv Stock Exchange dual listing

BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Maxim Group Maintains Buy on BioHarvest Sciences, Lowers Price Target to $5

Roth Capital Maintains Buy on BioHarvest Sciences, Lowers Price Target to $8

BioHarvest Sciences (BHST) Q2 2026 Earnings Call Transcript

BioHarvest Sciences Inc (BHST) (Q2 2026) Earnings Call Highlights: Strategic Pivot to ...

BioHarvest Sciences Inc. Common Stock Q2 2026 Earnings Call Summary

Conference Call: BioHarvest Sciences Lowers FY2026 Sales Guidance from $42.000M-$48.000M to $37.000M-$40.000M vs $42.914M Est